Representative of his experience are the following cases:

  • In re Eliquis Products Liability Litigation, MDL 2754 (S.D.N.Y.): National counsel for Bristol-Myers Squibb Co. and Pfizer in product liability litigation alleging that Eliquis causes bleeding, in which the DLA Piper team obtained landmark rulings finding that plaintiffs’ claims were preempted at the pleading stage (Utts v. Bristol-Myers Squibb Co., 226 F. Supp. 3d 166, 177 (S.D.N.Y. 2016) ("Utts I"); Utts v. Bristol-Myers Squibb Co., 251 F. Supp. 3d 644, 658 (S.D.N.Y. 2017) ("Utts II"). The MDL decisions were affirmed on appeal (Gibbons v. Bristol-Myers Squibb Co., No. 17-2638, 2d Cir. Mar. 26, 2019), a ruling the Drug & Device Law Blog called "the TwIqbal decision to end all TwIqbal decisions" in the preemption context and noted, "If anyone wonders why we consider preemption our side’s most powerful defense, Gibbons is Exhibit A."
  • In re Proton Pump Inhibitor Products Liability Litigation, MDL 2789 (D.N.J.): National counsel for Pfizer and Wyeth in product liability litigation alleging that proton pump inhibitors Protonix and Nexium 24HR (OTC) cause chronic kidney disease and other kidney injuries.
  • In re Viagra Products Liability Litigation,MDL 2691 (N.D. Cal.): Co-national counsel for Pfizer in product liability litigation alleging that Viagra causes melanoma.
  • Talc Product Liability Litigation: National counsel for BASF Catalysts LLC in nationwide litigation involving personal injuries allegedly caused by talc.
  • Tecfidera Litigation: Counsel for Biogen in personal injury suits involving MS medication.
  • In re Testosterone Replacement Therapy Products Liability Litigation, MDL 2545 (N.D. Ill.): National counsel for Pfizer and Pharmacia & Upjohn in product liability litigation involving testosterone replacement therapies; obtained orders dismissing all claims against clients, including failure-to-warn and design claims on basis of impossibility preemption, which were affirmed by 7th Circuit (Guilbeau v. Pfizer Inc., 2018 WL 476343 (7th Cir. Jan. 19, 2018)).
  • Rapamune Products Liability Litigation: Lead counsel for Pfizer and Wyeth in product liability litigation pending around the country involving immunosuppressant for use after organ transplantation.
  • In re Chantix (Varenicline) Products Liability Litigation, MDL 2092 (N.D. Ala.): Appointed by MDL court as Defendants' Liaison Counsel in product liability litigation involving Chantix, an aid to smoking cessation treatment; obtained ruling that label was adequate as a matter of law (In re Chantix (Varenicline) Prods. Liab. Litig., 881 F. Supp. 2d 1333 (N.D. Ala. 2012)).
  • Pepe v. Genzyme Corporation et al. (D. Mass.): Represented Genzyme in putative class action relating to DNA testing services.
  • In re Prempro Products Liability Litigation, 738 F. Supp. 2d 887 (E.D. Ark. 2010): Obtained ruling excluding plaintiffs’ experts’ opinion that estrogen-only hormone therapy causes breast cancer.
  • In re Bextra and Celebrex Marketing, Sales Practices and Products Liability Litigation,MDL No. 1699 (N.D. Cal.): Defended Pfizer in product liability and consumer fraud litigation involving selective COX-2 inhibitors; obtained exclusion of any expert opinions that Celebrex causes heart attacks and strokes at the most commonly prescribed dose (524 F.Supp. 2d 1166 (N.D. Cal. 2007)), which CNN.Money called "one of the most important 'gatekeeping' rulings ever rendered in a mass-tort case"; oversaw resolution program for thousands of cases.
  • Represented Pfizer in securities class action involving disclosures related to COX-2 inhibitors.
  • Baycol Litigation: Defended Bayer in product liability litigation involving Baycol, a prescription cholesterol-lowering medication; served on six trial teams in three states.
  • Buckingham v. Bayer Corporation (San Diego Superior Court): Obtained dismissal with prejudice of putative consumer fraud litigation against Bayer involving Aleve on preemption grounds.
  • Defended a clinical research organization in suits alleging breach of contract, conversion and trade secret misappropriation.
  • Represented students with special needs in proceedings against school districts relating to Individualized Education Programs, with a focus on children with autism spectrum disorder